🟢 EIQ.XA is trading 36% up today on U.S. leadership hires for FDA and commercial expansion

EIQ.XA is trading 36% up at A$1.68 after announcing key U.S.-focused leadership appointments to drive FDA initiatives and commercial expansion.

• The company named Matthew Dodds as Chief Financial Officer (effective June 2026) and heart specialist Dr. Vinod Thourani as a senior clinical leader.
• The strategic hires signal a stronger push into the U.S. cardiovascular market, significantly boosting investor optimism regarding the company's regulatory and growth prospects.